NASDAQ:EDIT Editas Medicine (EDIT) Stock Price, News & Analysis $2.62 0.00 (0.00%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$2.60 -0.02 (-0.76%) As of 10/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Editas Medicine Stock (NASDAQ:EDIT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Editas Medicine alerts:Sign Up Key Stats Today's Range$2.51▼$2.6350-Day Range$2.51▼$3.3052-Week Range$1.66▼$4.54Volume2.16 million shsAverage Volume3.07 million shsMarket Capitalization$402.38 millionP/E RatioN/ADividend YieldN/APrice Target$5.80Consensus RatingModerate Buy Company Overview Editas Medicine, Inc. is a biotechnology company focused on developing genomic medicines that use CRISPR-based gene-editing technologies to treat diseases caused by genetic abnormalities. The company’s research programs are designed to modify or correct disease-associated genes in patients’ cells, with the goal of developing potentially durable treatments. Its lead investigational program is reni-cel, formerly known as EDIT-301, an ex vivo CRISPR gene-editing therapy being studied for sickle cell disease and transfusion-dependent beta thalassemia. Editas has also pursued additional programs involving both ex vivo and in vivo gene editing, including potential treatments for genetic diseases affecting the blood and eyes. These therapies remain investigational and are subject to clinical and regulatory evaluation. Founded in 2013 and headquartered in Cambridge, Massachusetts, Editas Medicine conducts research and clinical development activities intended to serve patients internationally. The company was established by researchers and biotechnology industry professionals, including prominent scientists associated with the development of CRISPR gene-editing technology. Its business is centered on advancing proprietary gene-editing platforms and translating them into medicines for serious diseases with limited treatment options.AI Generated. May Contain Errors. Read More Editas Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreEDIT MarketRank™: Editas Medicine scored higher than 35% of companies evaluated by MarketBeat, and ranked 702nd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingEditas Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEditas Medicine has a consensus price target of $5.80, representing about 121.4% upside from its current price of $2.62.Amount of Analyst CoverageEditas Medicine has only been the subject of 3 research reports in the past 90 days.Read more about Editas Medicine's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Editas Medicine are expected to decrease in the coming year, from ($0.80) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 9.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Editas Medicine's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.13% of the float of Editas Medicine has been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 15.72, which indicates bearish sentiment.Change versus previous monthShort interest in Editas Medicine has recently decreased by 0.89%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Editas Medicine this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for EDIT on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows6 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,267.00 in company stock.Percentage Held by Insiders3.10% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Editas Medicine's insider trading history. Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EDIT Stock News HeadlinesEditas Medicine, Inc. (NASDAQ:EDIT) Stock Has Average Target Price of $5.801 hour ago | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Stock Crosses Below Fifty Day Moving Average - Here's What HappenedOctober 1, 2026 | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)Genmab A/S (NASDAQ:GMAB) versus Editas Medicine (NASDAQ:EDIT) Financial AnalysisSeptember 28, 2026 | americanbankingnews.comGuggenheim promuove Editas Medicine grazie alla terapia di editing genicoSeptember 24, 2026 | it.investing.comGuggenheim upgrades Editas Medicine to buy from neutralSeptember 23, 2026 | msn.comPerché il titolo Editas Medicine è in rialzo oggi?September 23, 2026 | it.investing.comEditas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 SharesSeptember 5, 2026 | insidertrades.comSee More Headlines EDIT Stock Analysis - Frequently Asked Questions How have EDIT shares performed this year? Editas Medicine's stock was trading at $2.05 at the beginning of 2026. Since then, EDIT shares have increased by 27.8% and is now trading at $2.62. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.12. The business earned $11.89 million during the quarter, compared to the consensus estimate of $2.85 million. Editas Medicine had a negative net margin of 157.32% and a negative trailing twelve-month return on equity of 196.63%. When did Editas Medicine IPO? Editas Medicine (EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Editas Medicine investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Tesla (TSLA), Enovix (ENVX) and Luminar Technologies (LAZR). Company Calendar Last Earnings8/05/2026Today10/05/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 EDIT's financial health is in the Green zone, according to TradeSmith. EDIT has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:EDIT CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees87Year Founded2013Price Target and Rating Average Price Target for Editas Medicine$5.80 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside+121.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$160.06 million Net Margins-157.32% Pretax Margin-157.32% Return on Equity-196.63% Return on Assets-38.17% Debt Debt-to-Equity RatioN/A Current Ratio3.19 Quick Ratio3.19 Sales & Book Value Annual Sales$40.52 million Price / Sales9.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book9.36Miscellaneous Outstanding Shares153,580,000Free Float148,819,000Market Cap$402.38 million OptionableOptionable Beta2.00 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:EDIT) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
